Molecular Cancer

Table 1 Correlation between BATF2 expression and clinicopathological characteristics of GC patients

From: m⁶A modification-mediated BATF2 acts as a tumor suppressor in gastric cancer through inhibition of ERK signaling

Variables	Internal cohort				External validation cohort
Variables	BATF2 low (n = 257)	BATF2 high (n = 95)	χ²	P	BATF2 low (n = 166)	BATF2 high (n = 66)	χ²	P
Age (years)			0.321	0.571			6.426	0.011*
< 65	152	53			99	51
≥ 65	105	42			67	15
Sex			4.504	0.034*			0.516	0.472
Female	58	32			48	16
Male	199	63			118	50
BMI			0.333	0.564
≤ 25	215	77
> 25	42	18
Tumor size (mm)			8.150	0.004*			0.003	0.953
< 50	121	61			110	44
≥ 50	136	34			56	22
Tumor location			5.238	0.155			6.130	0.105
Upper	83	22			40	21
Middle	46	14			66	31
Low	103	44			57	12
Overlap	25	15			3	2
Histological grade			5.180	0.023*			0.815	0.367
Well/Moderately	83	43			55	26
Poor	151	44			111	40
TNM stage			5.740	0.017*			7.758	0.005*
I&II	86	45			72	42
III&IV	171	50			94	24

*P < 0.05 was considered significant

Back to article page

ISSN: 1476-4598

Contact us

General enquiries: journalsubmissions@springernature.com